Merck & Co., Inc. (MRK) Position Lifted by Buckhead Capital Management LLC

Share on StockTwits

Buckhead Capital Management LLC increased its position in Merck & Co., Inc. (NYSE:MRK) by 12.0% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 17,142 shares of the company’s stock after buying an additional 1,830 shares during the quarter. Buckhead Capital Management LLC’s holdings in Merck & Co., Inc. were worth $1,041,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of MRK. Rockland Trust Co. purchased a new stake in Merck & Co., Inc. in the 2nd quarter worth $3,949,000. Middleton & Co Inc MA lifted its stake in Merck & Co., Inc. by 4.0% in the 1st quarter. Middleton & Co Inc MA now owns 157,307 shares of the company’s stock worth $8,569,000 after purchasing an additional 6,063 shares in the last quarter. Sawyer & Company Inc lifted its stake in Merck & Co., Inc. by 10.7% in the 2nd quarter. Sawyer & Company Inc now owns 22,984 shares of the company’s stock worth $1,395,000 after purchasing an additional 2,215 shares in the last quarter. Stephens Inc. AR lifted its stake in Merck & Co., Inc. by 2.7% in the 1st quarter. Stephens Inc. AR now owns 365,496 shares of the company’s stock worth $19,909,000 after purchasing an additional 9,526 shares in the last quarter. Finally, Bogart Wealth LLC purchased a new stake in Merck & Co., Inc. in the 2nd quarter worth $2,084,000. 72.20% of the stock is owned by institutional investors.

Several analysts have commented on the stock. Zacks Investment Research cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, June 18th. SunTrust Banks reiterated a “buy” rating and issued a $77.00 price target on shares of Merck & Co., Inc. in a research note on Thursday, August 16th. TheStreet upgraded shares of Merck & Co., Inc. from a “c+” rating to a “b-” rating in a research note on Friday, June 8th. BMO Capital Markets reiterated a “buy” rating and issued a $70.00 price target on shares of Merck & Co., Inc. in a research note on Sunday, July 22nd. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $59.00 price target on shares of Merck & Co., Inc. in a research note on Sunday, July 15th. Six equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Merck & Co., Inc. currently has an average rating of “Buy” and an average price target of $67.24.

In related news, Chairman Kenneth C. Frazier sold 228,091 shares of the company’s stock in a transaction dated Tuesday, July 31st. The shares were sold at an average price of $65.00, for a total transaction of $14,825,915.00. Following the transaction, the chairman now directly owns 938,788 shares in the company, valued at approximately $61,021,220. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Adam H. Schechter sold 134,094 shares of the company’s stock in a transaction dated Monday, June 18th. The shares were sold at an average price of $61.00, for a total transaction of $8,179,734.00. Following the transaction, the executive vice president now owns 100,000 shares in the company, valued at $6,100,000. The disclosure for this sale can be found here. Insiders have sold a total of 396,393 shares of company stock worth $25,235,061 over the last 90 days. Corporate insiders own 0.32% of the company’s stock.

Shares of NYSE MRK opened at $69.38 on Friday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.04 and a current ratio of 1.33. The stock has a market cap of $184.93 billion, a PE ratio of 17.43, a price-to-earnings-growth ratio of 2.36 and a beta of 0.81. Merck & Co., Inc. has a 12-month low of $52.83 and a 12-month high of $70.25.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Friday, July 27th. The company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.03. The firm had revenue of $10.47 billion for the quarter, compared to analysts’ expectations of $10.28 billion. Merck & Co., Inc. had a net margin of 3.67% and a return on equity of 32.68%. The business’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.01 EPS. sell-side analysts expect that Merck & Co., Inc. will post 4.27 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 5th. Stockholders of record on Monday, September 17th will be given a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a dividend yield of 2.77%. The ex-dividend date of this dividend is Friday, September 14th. Merck & Co., Inc.’s dividend payout ratio is 48.24%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

See Also: Diversification in Investing

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply